drugset / Trial / NCT03501056
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
Phase 2
Withdrawn
Fuda Cancer Hospital, Guangzhou
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced lung cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for lung cancer.
Timeline
- Start
- 2018-03-27
- Primary completion
- 2020-05-25
- Completion
- 2020-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Activated CIK | Cell therapy | — | — |
| Comparator | CD3-MUC1 Bispecific Antibody | Other / unclassified | — | — |